Symptomless liver condition linked to heart and kidney disease
A new review highlights that metabolic dysfunction-associated steatotic liver disease (MASLD) is a major, often overlooked risk factor for heart and kidney disease. Researchers propose a new framework to recognize the liver's role in cardiovascular-renal-hepatic-metabolic syndrome.
Why it matters
Recognizing the liver's systemic impact could change how clinicians assess and treat patients at risk for multi-organ failure.
by Mike Addelman, University of Manchester
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Schematic representation of the mechanisms across the cardiovascular-renal-hepatic-metabolic (CRHM) axis. Credit: Current Opinion in Nephrology & Hypertension (2026). DOI: 10.1097/mnh.0000000000001225 A common liver condition thought to be harmless could be dramatically increasing the risk of heart disease, kidney failure and premature death, according to a new review led by University of Manchester and Northern Care Alliance NHS Foundation Trust researchers.
Fatty liver disease, they find, has been overlooked in current approaches to assessing cardiometabolic health, despite growing evidence that it can play a central role in facilitating damage across different organs.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in